| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 49.6 | 33.9 | 49.5 |
| Other income | 0.2 | 0.0 | 0.0 |
| Total income | 49.8 | 33.9 | 49.5 |
| Profit before exceptional items & tax | -1.3 | -6.3 | -3.8 |
| Profit before tax | -1.3 | -6.3 | -3.8 |
| Net profit | -1.7 | -4.8 | -2.2 |
| Operating margin | -2.6% | -18.6% | -7.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +0.20% |
|---|
BSE results filing, NSE: SSORGS. Figures extracted from the filing.
Oxygenta Pharmaceutical Ltd: key numbers
- Share price
- ₹48.17
- Market cap
- ₹178.2 Cr
- Revenue (annual)
- ₹113.0 Cr
- Net profit (annual)
- ₹-17.57 Cr
- P/E (TTM)
- -13.1×Sector 47.4×
- Promoter holding
- 56.54%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Oxygenta Pharmaceutical Ltd
All →Oxygenta Pharmaceutical Annual General Meeting
Oxygenta Pharmaceutical Limited conducted its 33rd Annual General Meeting on August 21, 2026, via video conferencing to discuss and adopt various corporate business resolutions.
Oxygenta Pharmaceutical Annual Report
Oxygenta Pharmaceutical has submitted its 33rd Annual Report for FY 2025-26, including the notice for the upcoming Annual General Meeting scheduled for August 21, 2026.
Oxygenta Pharmaceutical Annual General Meeting
Oxygenta Pharmaceutical Limited announced its 33rd Annual General Meeting scheduled for August 21, 2026. The notice includes director appointments and adoption of the company's financial statements.
Oxygenta Pharmaceutical Other Announcement
Oxygenta Pharmaceutical Limited has appointed M/s. PCR & Associates as its Cost Auditor for a 12-month term. This appointment follows the company's recent board meeting.
Oxygenta Pharmaceutical Q1 FY27 Results: Net Loss of ₹2.1 Cr, Loss Narrows
Oxygenta Pharmaceutical Ltd reported revenue from operations of ₹37 Cr (+145.0% YoY) and a net loss of ₹2.1 Cr for Q1 FY27.
- Key figure
- Net loss ₹2.1 Cr
Oxygenta Pharmaceutical Board Meeting Date
Oxygenta Pharmaceutical Ltd has scheduled a board meeting on July 25, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026.